title: Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.
authors: Department of Endocrinology and Metabolism, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
authors: Peng-Fei
authors: PF
authors: Shan
authors: Department of Endocrinology and Metabolism, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
authors: Xiao-Li
authors: XL
authors: Ji
authors: Department of Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
authors: Liuhong
authors: L
authors: Wang
authors: Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
authors: Ping
authors: P
authors: Li
authors: Department of Endocrinology and Metabolism, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China renyuezhong@163.com.
authors: Yue-Zhong
authors: YZ
authors: Ren
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D000069036:Insulin Glargine / Q000494:pharmacology*; D000069450:Liraglutide / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects*; D008279:Magnetic Resonance Imaging; D008297:Male
chemical_list: D007004:Hypoglycemic Agents; D000069036:Insulin Glargine; D000069450:Liraglutide